Pharvaris (PHVS) Competitors $18.00 -0.60 (-3.23%) As of 07/7/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. SWTX, RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, and KYMRShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors SpringWorks Therapeutics Avidity Biosciences Ultragenyx Pharmaceutical Protagonist Therapeutics Ascentage Pharma Group International Scholar Rock MoonLake Immunotherapeutics Metsera Viking Therapeutics Kymera Therapeutics SpringWorks Therapeutics (NASDAQ:SWTX) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Which has higher valuation & earnings, SWTX or PHVS? Pharvaris has lower revenue, but higher earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78PharvarisN/AN/A-$145.24M-$3.01-5.98 Do analysts recommend SWTX or PHVS? SpringWorks Therapeutics presently has a consensus target price of $52.57, suggesting a potential upside of 11.88%. Pharvaris has a consensus target price of $36.20, suggesting a potential upside of 101.11%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SWTX or PHVS more profitable? Pharvaris has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -115.60%. SpringWorks Therapeutics' return on equity of -51.10% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-115.60% -51.10% -43.80% Pharvaris N/A -54.02%-50.36% Does the media prefer SWTX or PHVS? In the previous week, SpringWorks Therapeutics had 2 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for SpringWorks Therapeutics and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.22 beat SpringWorks Therapeutics' score of 0.93 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SpringWorks Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SWTX or PHVS? SpringWorks Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.82, meaning that its stock price is 382% less volatile than the S&P 500. SummaryPharvaris beats SpringWorks Therapeutics on 8 of the 13 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$972.60M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-5.9820.3027.1920.04Price / SalesN/A250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book3.257.397.925.55Net Income-$145.24M-$55.04M$3.17B$248.49M7 Day Performance4.35%2.51%1.78%4.87%1 Month Performance7.27%-0.21%1.26%6.63%1 Year Performance3.27%3.41%33.30%20.38% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.7441 of 5 stars$18.00-3.2%$36.20+101.1%+8.1%$972.60MN/A-5.9830Positive NewsGap UpSWTXSpringWorks Therapeutics1.5118 of 5 stars$46.99+0.0%$52.57+11.9%N/A$3.54B$191.59M-13.78230RNAAvidity Biosciences2.4611 of 5 stars$28.40-2.2%$65.59+130.9%-26.2%$3.50B$10.90M-9.47190RAREUltragenyx Pharmaceutical3.935 of 5 stars$36.36-0.4%$87.00+139.3%-3.1%$3.45B$560.23M-6.181,294PTGXProtagonist Therapeutics2.0636 of 5 stars$55.27-0.8%$66.10+19.6%+47.9%$3.45B$434.43M73.69120AAPGAscentage Pharma Group InternationalN/A$39.38-0.6%N/AN/A$3.45B$134.35M0.00600SRRKScholar Rock3.3045 of 5 stars$35.42-1.1%$42.67+20.5%+358.4%$3.40B$33.19M-14.00140MLTXMoonLake Immunotherapeutics1.955 of 5 stars$47.20-0.7%$74.50+57.8%+13.0%$3.04BN/A-20.522MTSRMetseraN/A$28.45-0.5%$55.00+93.3%N/A$3.00BN/A0.0081VKTXViking Therapeutics3.8404 of 5 stars$26.50-0.1%$87.15+228.9%-46.3%$2.98BN/A-23.0420KYMRKymera Therapeutics3.3151 of 5 stars$43.64-1.1%$59.61+36.6%+44.8%$2.87B$47.07M-14.08170 Related Companies and Tools Related Companies SpringWorks Therapeutics Alternatives Avidity Biosciences Alternatives Ultragenyx Pharmaceutical Alternatives Protagonist Therapeutics Alternatives Ascentage Pharma Group International Alternatives Scholar Rock Alternatives MoonLake Immunotherapeutics Alternatives Metsera Alternatives Viking Therapeutics Alternatives Kymera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts